Press Room

2020 CPhI - Festival of Pharma

Start
Monday, October 05, 2020 - 00:00
End
Friday, October 16, 2020 - 00:00
Location: online
Hovione Virtual Stand 2021 Online Booth | Hovione

Meet our experts at the pharma industry-leading events

 

Hovione is exhibiting at CPhI – Festival of Pharma 2020. You can sign up for free.

During the 10 days’ event, from October 5th to October 16th, you can meet with our experts safely online.

 

Hovione at a Glance | Hovione

Get to know more about our history

e-Brochures | Hovione

Explore what we are in it for

Integrated CDMO | Hovione

Webinars, Articles & More

Cork Site | Hovione

We welcome you to our sites

Analytical Development | Hovione

Our experts will help you

 

 

 

SOLVING YOUR CHALLENGES

Read the article from C&EN "One molecule’s journey from discovery to market" to find out how Hovione helped one customer solve their problem and succeed. More case studies will be available soon.

 

 

Subscribe to our newsletter and be the first to know.

 

 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026